413 related articles for article (PubMed ID: 16460136)
1. A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease.
Lamotte M; Annemans L; Evers T; Kubin M
Pharmacoeconomics; 2006; 24(2):155-69. PubMed ID: 16460136
[TBL] [Abstract][Full Text] [Related]
2. A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan.
Tsutani K; Igarashi A; Fujikawa K; Evers T; Kubin M; Lamotte M; Annemans L
Intern Med; 2007; 46(4):157-62. PubMed ID: 17301509
[TBL] [Abstract][Full Text] [Related]
3. Which patients should receive aspirin for primary prevention of cardiovascular disease? An economic evaluation.
Annemans L; Lamotte M; Kubin M; Evers T; Verheugt FW
Int J Clin Pract; 2006 Sep; 60(9):1129-37. PubMed ID: 16939558
[TBL] [Abstract][Full Text] [Related]
4. Clopidogrel: a pharmacoeconomic review of its use in patients with non-ST elevation acute coronary syndromes.
Lyseng-Williamson KA; Plosker GL
Pharmacoeconomics; 2006; 24(7):709-26. PubMed ID: 16802846
[TBL] [Abstract][Full Text] [Related]
5. [Health economic evaluation of low-dose acetylsalicylic acid in the primary prevention of cardiovascular disease].
Lamotte M; Piñol C; Brotons C; Annemans L; Guardiola E; Evers T; Kubin M
Rev Esp Cardiol; 2006 Aug; 59(8):807-15. PubMed ID: 16938230
[TBL] [Abstract][Full Text] [Related]
6. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
Logman JF; Heeg BM; Herlitz J; van Hout BA
Appl Health Econ Health Policy; 2010; 8(4):251-65. PubMed ID: 20578780
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
Kourlaba G; Fragoulakis V; Maniadakis N
Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
[TBL] [Abstract][Full Text] [Related]
8. Clopidogrel versus aspirin in patients with atherothrombosis: a CAPRIE-based cost-effectiveness model for Greece.
Kourlaba G; Fragoulakis V; Maniadakis N
Appl Health Econ Health Policy; 2012 Sep; 10(5):331-42. PubMed ID: 22853743
[TBL] [Abstract][Full Text] [Related]
9. A multi-country health-economic evaluation of highly concentrated n-3 polyunsaturated fatty acids in the secondary prevention after myocardial infarction.
Lamotte M; Annemans L; Kawalec P; Zoellners Y
Herz; 2006 Dec; 31 Suppl 3():74-82. PubMed ID: 17575809
[TBL] [Abstract][Full Text] [Related]
10. A multi-country health economic evaluation of highly concentrated N-3 polyunsaturated fatty acids in secondary prevention after myocardial infarction.
Lamotte M; Annemans L; Kawalec P; Zoellner Y
Pharmacoeconomics; 2006; 24(8):783-95. PubMed ID: 16898848
[TBL] [Abstract][Full Text] [Related]
11. Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model.
Schwander B; Gradl B; Zöllner Y; Lindgren P; Diener HC; Lüders S; Schrader J; Villar FA; Greiner W; Jönsson B
Value Health; 2009 Sep; 12(6):857-71. PubMed ID: 19508663
[TBL] [Abstract][Full Text] [Related]
12. Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany.
Brüggenjürgen B; Lindgren P; Ehlken B; Rupprecht HJ; Willich SN
Eur J Health Econ; 2007 Mar; 8(1):51-7. PubMed ID: 17186199
[TBL] [Abstract][Full Text] [Related]
13. An economic evaluation based on a randomized placebo-controlled trial of varenicline in smokers with cardiovascular disease: results for Belgium, Spain, Portugal, and Italy.
Wilson K; Hettle R; Marbaix S; Diaz Cerezo S; Ines M; Santoni L; Annemans L; Prignot J; Lopez de Sa E
Eur J Prev Cardiol; 2012 Oct; 19(5):1173-83. PubMed ID: 21840967
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: An Australian perspective.
Ademi Z; Zomer E; Tonkin A; Liew D
Int J Cardiol; 2018 Nov; 270():54-59. PubMed ID: 30220379
[TBL] [Abstract][Full Text] [Related]
15. Oral antiplatelet therapy in secondary prevention of cardiovascular events: an assessment from the payer's perspective.
Heeg B; Damen J; Van Hout B
Pharmacoeconomics; 2007; 25(12):1063-82. PubMed ID: 18047390
[TBL] [Abstract][Full Text] [Related]
16. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis.
Pignone M; Earnshaw S; Tice JA; Pletcher MJ
Ann Intern Med; 2006 Mar; 144(5):326-36. PubMed ID: 16520473
[TBL] [Abstract][Full Text] [Related]
17. Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis.
Pignone M; Earnshaw S; Pletcher MJ; Tice JA
Arch Intern Med; 2007 Feb; 167(3):290-5. PubMed ID: 17296886
[TBL] [Abstract][Full Text] [Related]
18. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
Liew D; Park HJ; Ko SK
Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
[TBL] [Abstract][Full Text] [Related]
19. [Incremental cost-effectiveness of dipyridamole + acetylsalicylic acid in secondary prevention of ischemic noncardioembolic stroke].
Claes C; Mittendorf T; Grond M; von der Schulenburg JM
Med Klin (Munich); 2008 Nov; 103(11):778-87. PubMed ID: 19165429
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.
Greving JP; Buskens E; Koffijberg H; Algra A
Circulation; 2008 Jun; 117(22):2875-83. PubMed ID: 18506010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
